Brokerage Firm Rating Update on ARIAD Pharmaceuticals (ARIA)

ARIAD Pharmaceuticals (ARIA) : 4 analysts are covering ARIAD Pharmaceuticals (ARIA) and their average rating on the stock is 2, which is read as a Buy. 3 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. However, 1 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock.

ARIAD Pharmaceuticals (ARIA) stock is expected to deviate a maximum of $1.83 from the average target price of $11 for the short term period. 4 Street Experts have initiated coverage on the stock with the most promising target being $13 and the most muted being $9.


For the current week, the company shares have a recommendation consensus of Buy. Also, Barclays maintains its view on ARIAD Pharmaceuticals (NASDAQ:ARIA) according to the research report released by the firm to its investors. The shares have now been rated Underweight by the stock experts at the ratings house. Barclays raises the price target from $8 per share to $9 per share on ARIAD Pharmaceuticals . The rating by the firm was issued on July 29, 2016.

ARIAD Pharmaceuticals (NASDAQ:ARIA): stock was range-bound between the intraday low of $10.28 and the intraday high of $10.475 after having opened at $10.43 on Wednesdays session. The stock finally closed in the red at $10.43, a loss of -0.19%. The stock remained in the red for the whole trading day. The total traded volume was 2,823,361 shares. The stock failed to cross $10.475 in Wednesdays trading. The stocks closing price on Thursday was $10.41.

ARIAD Pharmaceuticals, Inc. is a global oncology company. The Company is engaged in the discovery, development and commercialization of small molecule drug indicated for the treatment of cancer. The Companys product pipeline includes Iclusig (ponatinib), brigatinib (AP26113), AP32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI), which is approved in the United States, Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). AP32788, is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *